Experimental drug zervimesine made available to patients with lewy body dementia
NCT ID NCT06961760
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program offers the experimental drug zervimesine (CT1812) to people aged 50 to 86 with mild-to-moderate dementia with Lewy bodies. Participants take one 100 mg pill daily for up to a year. The goal is to provide access to the drug and collect long-term safety information.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zervimesine (CT1812)
What this could lead to
If this program shows that zervimesine is safe and well-tolerated over a year, it could support further research into a treatment for dementia with Lewy bodies.
What could go wrong
This is an expanded access program, not a formal trial, so it provides limited evidence of effectiveness. The drug is still experimental, and long-term risks are not fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA WITH LEWY BODIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner Sun Health Research Institute
Sun City, Arizona, 85351, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
Ohio State University Wexner Medical Center (OSUWMC)
Columbus, Ohio, 43210, United States
-
Stanford Neuroscience Heath Center
Palo Alto, California, 94304, United States
-
Summit Headlands LLC
Portland, Oregon, 97210, United States
-
University of Colorado Denver - Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
University of Miami - Department of Neurology
Boca Raton, Florida, 33433, United States